Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations
- PMID: 12782103
- DOI: 10.1016/S0161-813X(03)00030-5
Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations
Abstract
Plasma levels of parent compounds and metabolites were determined in adult rhesus monkeys after doses of either 5mg/kg d-fenfluramine (FEN) or 10mg/kg d-3, 4-methylenedioxymethamphetamine (MDMA) i.m. twice daily for four consecutive days. These treatment regimens have been previously shown to produce long-term serotonin (5-HT) depletions. Peak plasma levels of 2.0+/-0.4 microM FEN were reached within 40min after the first dose of FEN, and then declined rapidly, while peak plasma levels (0.4+/-0.1 microM) of the metabolite norfenfluramine (NFEN) were not reached until 6h after dosing. After the seventh (next to last) dose of FEN, peak plasma levels of FEN were 35% greater than after the first dose while peak NFEN-levels were 500% greater. The t(1/2) for FEN was 2.6+/-0.3h after the first dose and 3.2+/-0.2h after the seventh. The estimated t(1/2) for NFEN was more than 37.6+/-20.5h. Peak plasma levels of 9.5+/-2.5 microM MDMA were reached within 20min after the first dose of MDMA, and then declined rapidly, while peak plasma levels (0.9+/-0.2 microM) of the metabolite 3,4-methylenedioxyamphetamine (MDA) were not reached until 3-6h after dosing. After the seventh (next to last) dose of MDMA, peak plasma levels of MDMA were 30% greater than the first dose while peak MDA levels were elevated over 200%. The t(1/2) for MDMA was 2.8+/-0.4h after the first and 3.9+/-1.1h after the seventh dose. The estimated t(1/2) for MDA was about 8.3+/-1.0h. Variability in plasma levels of MDMA and MDA between subjects was much greater than that for FEN and NFEN. This variability in MDMA and MDA exposure levels may have lead to variability in the subsequent disruption of some behaviors seen in these same subjects. There were 80% reductions in the plasma membrane-associated 5-HT transporters 6 months after either the FEN or MDMA dosing regimen indicating that both treatments produced long-term serotonergic effects.
Similar articles
-
Acute effects of dexfenfluramine (d-FEN) and methylenedioxymethamphetamine (MDMA) before and after short-course, high-dose treatment.Ann N Y Acad Sci. 1998 May 30;844:183-90. Ann N Y Acad Sci. 1998. PMID: 9668676
-
Fenfluramine and norfenfluramine levels in brain microdialysate, brain tissue and plasma of rats administered doses of d-fenfluramine known to deplete 5-hydroxytryptamine levels in brain.J Pharmacol Exp Ther. 1998 Feb;284(2):618-24. J Pharmacol Exp Ther. 1998. PMID: 9454806
-
3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein.Synapse. 2004 Sep 15;53(4):240-8. doi: 10.1002/syn.20058. Synapse. 2004. PMID: 15266556
-
Ecstasy: are animal data consistent between species and can they translate to humans?J Psychopharmacol. 2006 Mar;20(2):194-210. doi: 10.1177/0269881106061153. J Psychopharmacol. 2006. PMID: 16510478 Review.
-
Cognitive Effects of MDMA in Laboratory Animals: A Systematic Review Focusing on Dose.Pharmacol Rev. 2019 Jul;71(3):413-449. doi: 10.1124/pr.118.017087. Pharmacol Rev. 2019. PMID: 31249067 Free PMC article.
Cited by
-
Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques.Neuroscience. 2006 Oct 13;142(2):515-25. doi: 10.1016/j.neuroscience.2006.06.033. Epub 2006 Jul 28. Neuroscience. 2006. PMID: 16876329 Free PMC article.
-
Could MDMA Promote Stemness Characteristics in Mouse Embryonic Stem Cells via mGlu5 Metabotropic Glutamate Receptors?Cell J. 2012 Fall;14(3):185-92. Epub 2012 Dec 12. Cell J. 2012. PMID: 23508940 Free PMC article.
-
Trace amine-associated receptors as emerging therapeutic targets.Mol Pharmacol. 2009 Aug;76(2):229-35. doi: 10.1124/mol.109.055970. Epub 2009 Apr 23. Mol Pharmacol. 2009. PMID: 19389919 Free PMC article. Review.
-
Δ9-Tetrahydrocannabinol attenuates MDMA-induced hyperthermia in rhesus monkeys.Neuroscience. 2012 Jan 10;201:125-33. doi: 10.1016/j.neuroscience.2011.11.040. Epub 2011 Nov 29. Neuroscience. 2012. PMID: 22138434 Free PMC article.
-
Serotonin neurotoxins--past and present.Neurotox Res. 2004;6(7-8):589-614. doi: 10.1007/BF03033455. Neurotox Res. 2004. PMID: 15639791 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical